Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study.

Autor: Faraldi F; Ophthalmology Unit, Surgical Department, A.O. Ordine Mauriziano, Turin, Italy.; Ophthalmology Unit, Surgical Department, ASL TO5, Chieri, Italy., Lavia CA; Ophthalmology Unit, Surgical Department, A.O. Ordine Mauriziano, Turin, Italy. carlo.lavia@gmail.com.; Ophthalmology Unit, Surgical Department, ASL TO5, Chieri, Italy. carlo.lavia@gmail.com., Nassisi M; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Kilian R; Ophthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy., Rizzo C; Ophthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy., Savastano MC; Ophthalmology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.; Catholic University 'Sacro Cuore', Rome, Italy., Rizzo S; Ophthalmology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.; Catholic University 'Sacro Cuore', Rome, Italy.; Italian National Research Council, CNR, Pisa, Italy.; Vitreoretinal Surgery Unit, 'Fatebenefratelli Isola Tiberina - Gemelli Isola' Hospital, Rome, Italy., Giansanti F; Neuromuscular and Sense Organs Department, Eye Clinic, Careggi University Hospital, Florence, Italy.; Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Bacherini D; Neuromuscular and Sense Organs Department, Eye Clinic, Careggi University Hospital, Florence, Italy.; Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Jazyk: angličtina
Zdroj: BMC ophthalmology [BMC Ophthalmol] 2024 Oct 04; Vol. 24 (1), pp. 436. Date of Electronic Publication: 2024 Oct 04.
DOI: 10.1186/s12886-024-03706-0
Abstrakt: Background: to analyze, at one year, the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients affected by macular neovascularization (MNV). Both naïve and previously treated (i.e., switched) patients were included, and the data from the two groups were compared.
Methods: anatomical (i.e., central subfoveal thickness, CST; presence of fluid), functional (i.e., best corrected visual acuity, BCVA) and treatment-related (i.e., number of IV injections within the study period; number of patients reaching a 12-weeks interval between treatments) data from 41 eyes of 41 subjects (20 naïve and 21 switched) were analyzed. Patients were treated with 3 monthly IV injections followed by a T&E regimen based on a disease activity assessment performed at each scheduled IV treatment.
Results: significant CST reduction (from 412.1 ± 115.8 to 273.2 ± 61.6; p < 0.05) and BCVA (mean; p) improvement were observed in the naïve group, while in the switched cohort, both parameters were almost stable. In the naïve and switched groups, 55% and 33.5% of patients, respectively, reached a 12-week IV interval at one year, with a mean of 6.55 ± 1 and 7.43 ± 0.68 IV treatments, respectively. One patient with mild anterior uveitis without sequelae was recorded.
Conclusion: In patients with MNV, IV Brolucizumab injections following a T&E regimen demonstrated great efficacy and a good safety profile, with greater anatomical and functional results in naïve patients.
Trial Registration: This study was approved by the Local Ethics Committee (protocol number 155/2020, general registry number n°11486, InterHospital Ethics Committee, San Luigi Gonzaga Hospital, Orbassano, Italy).
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: